Published in Pain on April 01, 1999
Clinical practice: Herpes zoster. N Engl J Med (2013) 5.16
Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther (2007) 2.65
Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag (2007) 2.59
Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med (2005) 1.96
[Reduction of chronic pain for non-postherpetic peripheral neuropathies after topical treatment with a lidocaine patch]. Schmerz (2004) 1.42
Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol (2008) 1.25
Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain (2006) 1.21
Topical preparations for pain relief: efficacy and patient adherence. J Pain Res (2010) 1.17
Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol (2005) 1.07
Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol (2004) 1.03
The pharmacotherapy of chronic pain: a review. Pain Res Manag (2006) 1.01
Brain dynamics for perception of tactile allodynia (touch-induced pain) in postherpetic neuralgia. Pain (2008) 1.01
Diabetic neuropathy part 1: overview and symmetric phenotypes. Neurol Clin (2013) 0.99
Governing role of primary afferent drive in increased excitation of spinal nociceptive neurons in a model of sciatic neuropathy. Exp Neurol (2008) 0.92
Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster. Local Reg Anesth (2010) 0.90
Postherpetic neuralgia: from preclinical models to the clinic. Neurotherapeutics (2009) 0.86
Treatment of neuropathic pain with 5% lidocaine-medicated plaster: Five years of clinical experience. Pain Res Manag (2011) 0.86
Neuropathic cancer pain: What we are dealing with? How to manage it? Onco Targets Ther (2014) 0.83
Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Support Care Cancer (2009) 0.81
Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag (2009) 0.81
The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence. J Pain Res (2016) 0.79
Analgesia for patients with advanced disease: 2. Postgrad Med J (2004) 0.78
Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review. BMC Neurol (2010) 0.78
Bottlenecks in the development of topical analgesics: molecule, formulation, dose-finding, and phase III design. J Pain Res (2017) 0.78
[Interdisciplinary guidance for pain management in nursing home residents]. Z Gerontol Geriatr (2012) 0.77
Shingles (Herpes Zoster) and Post-herpetic Neuralgia. Curr Treat Options Neurol (2001) 0.77
[Types of topical treatment for peripheral neuropathic pain : Mechanism of action and indications]. Schmerz (2010) 0.77
5% Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability. Pain Ther (2015) 0.77
5% lidocaine medicated plaster double effect in a case of orofacial localized neuropathic pain. J Pain Res (2014) 0.76
Preemptive perineural bupivacaine attenuates the maintenance of mechanical and cold allodynia in a rat spinal nerve ligation model. BMC Anesthesiol (2015) 0.75
Lidocaine 5 % patches as an effective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer (2013) 0.75
The 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its Use. Pain Ther (2016) 0.75
Topical Treatments for Localized Neuropathic Pain. Curr Pain Headache Rep (2017) 0.75
Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia. Clinicoecon Outcomes Res (2013) 0.75
Mexiletine therapy for chronic pain: survival analysis identifies factors predicting clinical success. J Pain Symptom Manage (2008) 0.75
Topical lidocaine patch 5% for acute postoperative pain control. BMJ Case Rep (2011) 0.75
Intravenous Lidocaine for Refractory Chronic Orofacial Pain: Two case reports and a literature review. Sultan Qaboos Univ Med J (2008) 0.75
Presentation and management of herpes zoster (shingles) in the geriatric population. P T (2013) 0.75
Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med (1991) 7.17
Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science (1968) 3.69
Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell (1992) 3.20
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol (1997) 3.11
Can the uptake of breast screening by Asian women be increased? A randomized controlled trial of a linkworker intervention. J Public Health Med (1994) 3.04
Managed care: devils, angels, and the truth in between. Health Prog (1999) 2.68
Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ (1998) 2.61
Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology (2007) 2.55
Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol (1974) 2.51
Pigmentary epitheliopathy and erythema nodosum. Arch Ophthalmol (1971) 2.39
Detection and surveillance of colorectal cancer. JAMA (1989) 2.07
Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time. J Virol (1996) 1.98
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology (2006) 1.97
Case report. Metastatic pulmonary calcification in renal failure: a new HRCT pattern. Br J Radiol (2002) 1.95
The International Collaborative Study of Maternal Phenylketonuria: status report 1998. Eur J Pediatr (2000) 1.91
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer. JAMA (1996) 1.90
Mutations of the Gs alpha-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. Proc Natl Acad Sci U S A (1990) 1.82
Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer (2007) 1.77
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet (2002) 1.77
What price survival? The future of Blue Cross and Blue Shield. JAMA (1998) 1.75
Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet (2004) 1.73
Neurologic aspects of cocaine abuse. West J Med (1988) 1.71
A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet (1997) 1.71
The uninsured. From dilemma to crisis. JAMA (1991) 1.65
Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab (1996) 1.65
Slicing the pie thinner: hospitals and physicians square off over primary care services. Hospitals (1982) 1.64
The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol (2000) 1.63
Impaired learning in mice with abnormal short-lived plasticity. Curr Biol (1996) 1.63
Coping with calamity. How well does health care disaster planning work? JAMA (1994) 1.61
Prediction of early course of breast carcinoma by thymidine labeling. Cancer (1983) 1.61
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60
What is a "clinically meaningful" reduction in pain? Pain (2001) 1.57
The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology (2012) 1.56
Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation (2001) 1.56
New evidence for neurotransmitter influences on brain development. Trends Neurosci (1997) 1.53
Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry (1992) 1.53
ATM haplotypes and breast cancer risk in Jewish high-risk women. Br J Cancer (2006) 1.47
Mirk protein kinase is a mitogen-activated protein kinase substrate that mediates survival of colon cancer cells. Cancer Res (2000) 1.40
Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science (1992) 1.40
A demanding issue. Healthc Forum J (1996) 1.39
Changing the ranks of medicine. Women MDs. Med World News (1988) 1.39
Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience (2005) 1.38
Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer (2007) 1.38
Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J Pharmacol Exp Ther (1990) 1.37
The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet (1998) 1.37
Induction of SOS functions by alkaline intracellular pH in Escherichia coli. J Bacteriol (1986) 1.36
Digital indocyanine-green angiography in chorioretinal disorders. Ophthalmology (1992) 1.35
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2004) 1.34
Public hospitals: doing what everyone wants done but few others wish to do. JAMA (1987) 1.34
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2012) 1.34
Money isn't everything. Nonfinancial barriers to access. JAMA (1994) 1.34
Squamous cell carcinoma of the transverse duodenum. Gastrointest Endosc (1986) 1.33
Pre-oligodendrocytes from adult human CNS. J Neurosci (1992) 1.29
Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem (1994) 1.28
Disciform degeneration of the macula. II. Pathogenesis. Arch Ophthalmol (1976) 1.26
A new human experimental pain model: the heat/capsaicin sensitization model. Neuroreport (1999) 1.26
Hippocampus-dependent learning and memory is impaired in mice lacking the Ras-guanine-nucleotide releasing factor 1 (Ras-GRF1). Neuropharmacology (2001) 1.24
Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci U S A (1991) 1.23
Limited form of Wegener granulomatosis. Eye involvement as a major sign. JAMA (1975) 1.23
In utero cocaine-induced dysfunction of dopamine D1 receptor signaling and abnormal differentiation of cerebral cortical neurons. J Neurosci (2000) 1.20
Natural history of disciform degeneration of the macula. Am J Ophthalmol (1974) 1.20
Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain (2000) 1.18
Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. Mol Pharmacol (1995) 1.16
The effect of systemic lidocaine on pain and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy volunteers. Anesth Analg (2000) 1.14
The retinal pigment epithelium. 3. Growth and development. Arch Ophthalmol (1968) 1.14
The retinal pigment epithelium. IV. The damaging effects of radiant energy. Arch Ophthalmol (1968) 1.12
Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem (1994) 1.12
No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA (1994) 1.12
Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium. Cancer Res (1986) 1.11
Prenatal exposure to cocaine selectively reduces D1 dopamine receptor-mediated activation of striatal Gs proteins. J Pharmacol Exp Ther (1995) 1.09
The retinal pigment epithelium. I. Comparative histology. Arch Ophthalmol (1967) 1.09
Effect of remifentanil on pain and secondary hyperalgesia associated with the heat--capsaicin sensitization model in healthy volunteers. Anesthesiology (2001) 1.08
Acute glomerulonephritis associated with varicella infection. Am J Med (1968) 1.08
Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage (2000) 1.08
Ibotenate lesions of the hippocampus impair spatial learning but not contextual fear conditioning in mice. Behav Brain Res (1999) 1.08
Naevoid basal cell carcinoma syndrome and Charcot-Marie-Tooth disease: two autosomal dominant disorders segregating in a family. J Med Genet (1978) 1.08
Family planning services for persons handicapped by mental retardation. Am J Public Health (1976) 1.07
Childhood abuse as a risk for partner abuse among women in methadone maintenance. Am J Drug Alcohol Abuse (1997) 1.07
Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat (2000) 1.07
Pre-endoscopic medication: parenteral diazepam used adjunctively. Gastrointest Endosc (1970) 1.06
Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res (1991) 1.06
Association of fragile X syndrome with autism. Lancet (1982) 1.06
Update of the vascular model of AMD. Br J Ophthalmol (2004) 1.05
Public hospitals often face unmet capital needs, underfunding, uncompensated patient-care costs. JAMA (1987) 1.05
Autism is associated with the fragile-X syndrome. J Autism Dev Disord (1982) 1.05
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer (2000) 1.05
The sagging safety net. Emergency departments on the brink of crisis. Hospitals (1992) 1.05
Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions. J Neurochem (2001) 1.04
Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer (2000) 1.04
The retinal pigment epithelium. II. Histologic changes associated with age. Arch Ophthalmol (1968) 1.03
Long-term prognosis after first Q-wave (transmural) or non-Q-wave (nontransmural) myocardial infarction: analysis of 593 patients. Am J Cardiol (1983) 1.03
Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry (1996) 1.03
Pediatric aerodigestive foreign body injuries are complications related to timeliness of diagnosis. Laryngoscope (1997) 1.02
Metastatic Peptostreptococcus intermedius endophthalmitis after a dental procedure. Am J Ophthalmol (1978) 1.02
Transforming growth factor beta 1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation. Cell Growth Differ (1990) 1.01
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer (2001) 1.01
Systemic tuberculosis initially seen as an oral ulceration: report of case. J Oral Surg (1978) 1.01